...
首页> 外文期刊>Pharmacoepidemiology and drug safety >A comparison of antidepressant use in Nova Scotia, Canada and Australia.
【24h】

A comparison of antidepressant use in Nova Scotia, Canada and Australia.

机译:在新斯科舍省,加拿大和澳大利亚使用抗抑郁药的比较。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

PURPOSE: The prevalence of major depression is reported as approximately 8% in Canada and 7.5% in Australia, the use of antidepressants is therefore common. However, questions remain about whether depression is under-diagnosed and whether patients are appropriately treated with antidepressants once the disorder is recognized. We compared the use of antidepressant medicines, in Nova Scotia, Canada and Australia, in populations receiving public drug subsidy. METHODS: The Nova Scotia Pharmacare Program and the Pharmaceutical Benefits Scheme in Australia were used to obtain dispensing data for all publicly subsidized antidepressants. Utilization was compared from 2000-2003, using the World Health Organisation Anatomic Therapeutic Chemical (ATC)/Defined Daily Dose (DDD) system. RESULTS: The use of antidepressants increased in both areas over the study period. However, the use of antidepressants in Nova Scotia increased at a significantly higher rate than Australia. Selective serotonin reuptake inhibitors (SSRIs) were the most commonly prescribed class of drugs in both areas, constituting 60% of all antidepressants prescribed. Eight different antidepressants made up 90% of the antidepressant drug use in Australia, with sertraline the most commonly prescribed. Similarly, nine different antidepressants made up 90% of the antidepressant use in Nova Scotia, with paroxetine most commonly prescribed. CONCLUSIONS: This study found differences in the rate but not class of antidepressant prescribing in Nova Scotia and Australia. Antidepressant use increased in both areas over the time period. This may be due to increased exposure to marketing, promotion, education or different prescribing practices in Nova Scotia compared to Australia. Copyright (c) 2008 John Wiley & Sons, Ltd.
机译:目的:据报道,加拿大的重度抑郁症患病率约为8%,澳大利亚为7.5%,因此使用抗抑郁药很普遍。但是,一旦认识到抑郁症,是否对抑郁症的诊断不足以及是否对患者进行抗抑郁药的治疗仍然存在疑问。我们比较了新斯科舍省,加拿大和澳大利亚在接受公共药物补贴的人群中使用抗抑郁药的情况。方法:澳大利亚的新斯科舍省药品计划和药品福利计划用于获取所有公共补贴的抗抑郁药的配药数据。使用世界卫生组织解剖治疗化学(ATC)/确定的每日剂量(DDD)系统比较了2000年至2003年的利用率。结果:在研究期间,这两个地区抗抑郁药的使用均增加。但是,新斯科舍省抗抑郁药的使用率明显高于澳大利亚。选择性5-羟色胺再摄取抑制剂(SSRIs)是这两个领域中最常用的处方药,占处方的所有抗抑郁药的60%。八种不同的抗抑郁药占澳大利亚抗抑郁药使用量的90%,其中舍曲林是最常用的处方药。同样,在新斯科舍省,九种不同的抗抑郁药占抗抑郁药使用量的90%,其中最常见的是帕罗西汀。结论:本研究发现新斯科舍省和澳大利亚的抗抑郁药处方率不同,但没有差异。在这段时间内,这两个地区的抗抑郁药使用量均有增加。与澳大利亚相比,这可能是由于新斯科舍省增加了对营销,促销,教育或不同处方方法的了解。版权所有(c)2008 John Wiley&Sons,Ltd.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号